IL145710A0 - Methods for preventing or attenuating pathoangiogenic conditions - Google Patents
Methods for preventing or attenuating pathoangiogenic conditionsInfo
- Publication number
- IL145710A0 IL145710A0 IL14571001A IL14571001A IL145710A0 IL 145710 A0 IL145710 A0 IL 145710A0 IL 14571001 A IL14571001 A IL 14571001A IL 14571001 A IL14571001 A IL 14571001A IL 145710 A0 IL145710 A0 IL 145710A0
- Authority
- IL
- Israel
- Prior art keywords
- gbs toxin
- methods
- attenuating
- preventing
- toxin receptor
- Prior art date
Links
- 239000003053 toxin Substances 0.000 abstract 6
- 231100000765 toxin Toxicity 0.000 abstract 6
- 108700012359 toxins Proteins 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17987000P | 2000-02-02 | 2000-02-02 | |
PCT/US2001/003662 WO2001056598A2 (en) | 2000-02-02 | 2001-02-02 | Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145710A0 true IL145710A0 (en) | 2002-07-25 |
Family
ID=22658332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14571001A IL145710A0 (en) | 2000-02-02 | 2001-02-02 | Methods for preventing or attenuating pathoangiogenic conditions |
Country Status (14)
Country | Link |
---|---|
US (1) | US20020061846A1 (zh) |
EP (1) | EP1198246B1 (zh) |
JP (1) | JP2003521523A (zh) |
KR (1) | KR20020001817A (zh) |
CN (1) | CN100400100C (zh) |
AT (1) | ATE465751T1 (zh) |
AU (2) | AU782853B2 (zh) |
BR (1) | BR0104357A (zh) |
CA (1) | CA2369050A1 (zh) |
DE (1) | DE60141938D1 (zh) |
IL (1) | IL145710A0 (zh) |
MX (1) | MXPA01009917A (zh) |
NO (1) | NO20014772L (zh) |
WO (1) | WO2001056598A2 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8609614B2 (en) * | 1998-07-22 | 2013-12-17 | Vanderbilt University | GBS toxin receptor compositions and methods of use |
US6803448B1 (en) * | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
GB0227026D0 (en) * | 2002-11-20 | 2002-12-24 | Molecular Skincare Ltd | Psoriasis diagnostics and therapeutics |
KR101163800B1 (ko) | 2003-10-15 | 2012-07-09 | 산텐 세이야꾸 가부시키가이샤 | 신규 인다졸 유도체 |
CN113905754A (zh) * | 2019-01-25 | 2022-01-07 | 詹森药业有限公司 | 减轻起疱剂和腐蚀性气体毒性作用的方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
US5010062A (en) * | 1989-09-25 | 1991-04-23 | Vanderbilt University | Therapeutic agent and method of inhibiting vascularization of tumors |
US5858991A (en) * | 1997-01-29 | 1999-01-12 | Vanderbilt University | Facilitation of wound healing with CM101/GBS toxin |
EP1098978B1 (en) | 1998-07-22 | 2010-09-15 | Vanderbilt University | Gbs toxin receptor |
US6803448B1 (en) * | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
-
2001
- 2001-02-02 DE DE60141938T patent/DE60141938D1/de not_active Expired - Lifetime
- 2001-02-02 WO PCT/US2001/003662 patent/WO2001056598A2/en active Application Filing
- 2001-02-02 CN CNB018005993A patent/CN100400100C/zh not_active Expired - Fee Related
- 2001-02-02 JP JP2001556497A patent/JP2003521523A/ja active Pending
- 2001-02-02 CA CA002369050A patent/CA2369050A1/en not_active Abandoned
- 2001-02-02 EP EP01906979A patent/EP1198246B1/en not_active Expired - Lifetime
- 2001-02-02 US US09/776,865 patent/US20020061846A1/en not_active Abandoned
- 2001-02-02 IL IL14571001A patent/IL145710A0/xx unknown
- 2001-02-02 AU AU34817/01A patent/AU782853B2/en not_active Ceased
- 2001-02-02 KR KR1020017012595A patent/KR20020001817A/ko not_active Application Discontinuation
- 2001-02-02 AT AT01906979T patent/ATE465751T1/de not_active IP Right Cessation
- 2001-02-02 MX MXPA01009917A patent/MXPA01009917A/es unknown
- 2001-02-02 BR BR0104357-9A patent/BR0104357A/pt not_active IP Right Cessation
- 2001-10-01 NO NO20014772A patent/NO20014772L/no unknown
-
2009
- 2009-10-16 AU AU2009227821A patent/AU2009227821A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
MXPA01009917A (es) | 2003-08-01 |
KR20020001817A (ko) | 2002-01-09 |
AU3481701A (en) | 2001-08-14 |
EP1198246A2 (en) | 2002-04-24 |
NO20014772L (no) | 2001-11-12 |
WO2001056598A3 (en) | 2002-02-14 |
JP2003521523A (ja) | 2003-07-15 |
WO2001056598A2 (en) | 2001-08-09 |
CN1372474A (zh) | 2002-10-02 |
BR0104357A (pt) | 2002-05-21 |
CN100400100C (zh) | 2008-07-09 |
AU782853B2 (en) | 2005-09-01 |
US20020061846A1 (en) | 2002-05-23 |
CA2369050A1 (en) | 2001-08-09 |
AU2009227821A1 (en) | 2009-11-05 |
DE60141938D1 (de) | 2010-06-10 |
NO20014772D0 (no) | 2001-10-01 |
EP1198246B1 (en) | 2010-04-28 |
ATE465751T1 (de) | 2010-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002058717A3 (en) | Methods for treating rheumatoid arthritis using il-17 antagonists | |
MXPA03004793A (es) | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. | |
WO2002081646A3 (en) | Epitope sequences | |
DE60142794D1 (de) | Antikörper gegen cd28 | |
WO2004022709A3 (en) | Epitope sequences | |
MXPA02007756A (es) | Anticuerpos que aglutinan interleuqina-18 humana y metodos de fabricacion y uso. | |
ATE200679T1 (de) | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen | |
ES2191016T3 (es) | Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial. | |
ES2141467T3 (es) | Anticuerpos anti-cd 30 que impiden la escision proteolitica y liberacion del antigeno cd-30 fijado a la membrana. | |
DK1042001T3 (da) | Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner | |
ES2293973T3 (es) | Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos. | |
IL166659A0 (en) | Nogo receptor antagonists | |
DE60235588D1 (de) | Monoklonales Antikörper gegen das HCV Kernantigen | |
EP0866133A3 (en) | A group b streptococcus vaccine | |
BR9809656A (pt) | Composição imunopotencializante | |
BR0314369A (pt) | Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado | |
ES2196150T3 (es) | Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion. | |
IL145710A0 (en) | Methods for preventing or attenuating pathoangiogenic conditions | |
TR200103432T2 (tr) | Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı. | |
ATE359821T1 (de) | Bor-neutronenfangtherapie unter verwendung von pre-targeting-methoden | |
WO2000037102A3 (en) | Improvement of tolerance to a xenograft | |
GB9715177D0 (en) | Medicament | |
CA2347278A1 (en) | Vaccine based on attenuated haemophilus somnus | |
UA93478C2 (ru) | Выделенное моноклональное антитело человека, kotopoe связывается c cd20, и его применение | |
MX9709446A (es) | Metodo para preparar un anticuerpo monoclonal, anticuerpo monoclonal, una composicion farmaceutica y un reactivo de diagnostico. |